These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 28245872)

  • 1. Public sector low threshold office-based buprenorphine treatment: outcomes at year 7.
    Bhatraju EP; Grossman E; Tofighi B; McNeely J; DiRocco D; Flannery M; Garment A; Goldfeld K; Gourevitch MN; Lee JD
    Addict Sci Clin Pract; 2017 Feb; 12(1):7. PubMed ID: 28245872
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Home buprenorphine/naloxone induction in primary care.
    Lee JD; Grossman E; DiRocco D; Gourevitch MN
    J Gen Intern Med; 2009 Feb; 24(2):226-32. PubMed ID: 19089508
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Unobserved versus observed office buprenorphine/naloxone induction: a pilot randomized clinical trial.
    Gunderson EW; Wang XQ; Fiellin DA; Bryan B; Levin FR
    Addict Behav; 2010 May; 35(5):537-40. PubMed ID: 20106601
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Unobserved "home" induction onto buprenorphine.
    Lee JD; Vocci F; Fiellin DA
    J Addict Med; 2014; 8(5):299-308. PubMed ID: 25254667
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Buprenorphine prescribing practice trends and attitudes among New York providers.
    Kermack A; Flannery M; Tofighi B; McNeely J; Lee JD
    J Subst Abuse Treat; 2017 Mar; 74():1-6. PubMed ID: 28132694
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Telemedicine Buprenorphine Clinic to Serve New York City: Initial Evaluation of the NYC Public Hospital System's Initiative to Expand Treatment Access During the COVID-19 Pandemic.
    Tofighi B; McNeely J; Walzer D; Fansiwala K; Demner A; Chaudhury CS; Subudhi I; Schatz D; Reed T; Krawczyk N
    J Addict Med; 2022 Jan-Feb 01; 16(1):e40-e43. PubMed ID: 33560696
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Primary care-based buprenorphine taper vs maintenance therapy for prescription opioid dependence: a randomized clinical trial.
    Fiellin DA; Schottenfeld RS; Cutter CJ; Moore BA; Barry DT; O'Connor PG
    JAMA Intern Med; 2014 Dec; 174(12):1947-54. PubMed ID: 25330017
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical experience with fortnightly buprenorphine/naloxone versus buprenorphine in Italy: preliminary observational data in an office-based setting.
    Amato P
    Clin Drug Investig; 2010; 30 Suppl 1():33-9. PubMed ID: 20450244
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Home- versus office-based buprenorphine inductions for opioid-dependent patients.
    Sohler NL; Li X; Kunins HV; Sacajiu G; Giovanniello A; Whitley S; Cunningham CO
    J Subst Abuse Treat; 2010 Mar; 38(2):153-9. PubMed ID: 19801178
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized trial of buprenorphine maintenance for heroin dependence in a primary care clinic for substance users versus a methadone clinic.
    O'Connor PG; Oliveto AH; Shi JM; Triffleman EG; Carroll KM; Kosten TR; Rounsaville BJ; Pakes JA; Schottenfeld RS
    Am J Med; 1998 Aug; 105(2):100-5. PubMed ID: 9727815
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Persistence and healthcare utilization associated with the use of buprenorphine/naloxone film and tablet formulation therapy in adults with opioid dependence.
    Clay E; Khemiri A; Zah V; Aballéa S; Ruby J; Asche CV
    J Med Econ; 2014 Sep; 17(9):626-36. PubMed ID: 24841329
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Effect of a Payer-Mandated Decrease in Buprenorphine Dose on Aberrant Drug Tests and Treatment Retention Among Patients with Opioid Dependence.
    Accurso AJ; Rastegar DA
    J Subst Abuse Treat; 2016 Feb; 61():74-9. PubMed ID: 26639639
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inpatient initiation of buprenorphine maintenance vs. detoxification: can retention of opioid-dependent patients in outpatient counseling be improved?
    Caldiero RM; Parran TV; Adelman CL; Piche B
    Am J Addict; 2006; 15(1):1-7. PubMed ID: 16449087
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Primary care office-based buprenorphine treatment: comparison of heroin and prescription opioid dependent patients.
    Moore BA; Fiellin DA; Barry DT; Sullivan LE; Chawarski MC; O'Connor PG; Schottenfeld RS
    J Gen Intern Med; 2007 Apr; 22(4):527-30. PubMed ID: 17372805
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of a sublingual buprenorphine/naloxone rapidly dissolving tablet for the treatment of adults with opioid dependence: A randomized trial.
    Webster L; Hjelmström P; Sumner M; Gunderson EW
    J Addict Dis; 2016; 35(4):325-338. PubMed ID: 27267785
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low barrier buprenorphine treatment for persons experiencing homelessness and injecting heroin in San Francisco.
    Carter J; Zevin B; Lum PJ
    Addict Sci Clin Pract; 2019 May; 14(1):20. PubMed ID: 31060600
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of incarceration history on outcomes of primary care office-based buprenorphine/naloxone.
    Wang EA; Moore BA; Sullivan LE; Fiellin DA
    J Gen Intern Med; 2010 Jul; 25(7):670-4. PubMed ID: 20213205
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Consensus statement on office-based treatment of opioid dependence using buprenorphine.
    Fiellin DA; Kleber H; Trumble-Hejduk JG; McLellan AT; Kosten TR
    J Subst Abuse Treat; 2004 Sep; 27(2):153-9. PubMed ID: 15450648
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A naturalistic study of predictors of retention in treatment among emerging adults entering first buprenorphine maintenance treatment for opioid use disorders.
    Dayal P; Balhara YPS
    J Subst Abuse Treat; 2017 Sep; 80():1-5. PubMed ID: 28755768
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The association between cocaine use and treatment outcomes in patients receiving office-based buprenorphine/naloxone for the treatment of opioid dependence.
    Sullivan LE; Moore BA; O'Connor PG; Barry DT; Chawarski MC; Schottenfeld RS; Fiellin DA
    Am J Addict; 2010; 19(1):53-8. PubMed ID: 20132122
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.